A pan-European registry-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis (Dream to TREAT AD)

First published 12/01/2024

Last updated 10/03/2025

EU PAS number:

EUPAS108468

Study

Finalised

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

A pan-European registry-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis (Dream to TREAT AD)

Secondary tabs

Share this page